ArticleBMC gastroenterology2025
CTI as a biomarker for diarrhea in U.S. adults: insights from NHANES 2005-2010.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of the CRP-TyG index for in-hospital and 1-year mortality in patients with decompensated heart failure.BMC cardiovascular disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe C-Reactive protein-triglyceride-glucose index (CTI), a novel composite biomarker integrating inflammation and insulin resistance, has shown promise in predicting metabolic and inflammatory outcomes. However, its association with bowel dysfunction remains unexplored.
methodsThis population-based cross-sectional study utilized data from the National Health and Nutrition Examination Survey (NHANES) 2005–2010 cycles. A total of 4,165 participants were included after rigorous exclusion criteria. CTI was calculated using the formula: 0.412 × Ln(CRP) + TyG, where TyG represents the triglyceride-glucose index. Diarrhea and constipation were defined based on the Bristol Stool Form Scale and bowel frequency. Logistic regressions were employed to assess associations between CTI and bowel dysfunction. Subgroup and mediation analyses were conducted to explore potential effect modifications and underlying mechanisms.
resultsHigher CTI levels were significantly associated with increased diarrhea risk (adjusted OR = 1.58, 95% CI: 1.20–2.10, P < 0.05), with a dose–response relationship observed across CTI quartiles (P for trend = 0.047). No significant association was found between CTI and constipation (P > 0.05). Subgroup analyses revealed consistent associations across most demographic and clinical characteristics, with no significant interaction effects (all P for interaction > 0.05). Mediation analysis revealed that body mass index (BMI), waistline and hypertension significantly mediated the association between CTI and diarrhea.
conclusionCTI is associated with the occurrence of diarrhea and may serve as a useful biomarker for identifying individuals at higher risk of diarrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.